A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Recruiting

Phase 1

Phase 2

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid MalignanciesA Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

Sponsor:

AstraZeneca

Code:

NCT05123482

Conditions

Breast Cancer

Biliary Tract Carcinoma

Ovarian Cancer

Endometrial Cancer

Squamous Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AZD8205

AZD8205 and AZD2936 (Rilvegostomig)

AZD8205 and AZD5305 (saruparib)

AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-25. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-02-21.